



Attorney Docket No.: 10322.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yaver et al.

Confirmation No: To be assigned

Serial No.: 10/656,055

Group Art Unit: To be assigned

Filed: September 5, 2003

Examiner: To be assigned

For: Methods for Identifying Markers of Antimicrobial Compounds

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO/SB/08A
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on December 2, 2003.

Seleste Buriani

(name of person mailing paper)

Seleste Buriani

(signature of person mailing paper)



Attorney Docket No.: 10322.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Yaver et al.

Confirmation No: To be assigned

Serial No.: 10/656,055

Group Art Unit: To be assigned

Filed: September 5, 2003

Examiner: To be assigned

For: Methods for Identifying Markers of Antimicrobial Compounds

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: December 2, 2003

Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/656,055
				Filing Date	September 5, 2003
				First Named Inventor	Yaver et al.
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	10322.200-US
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/656,055
				Filing Date	September 5, 2003
				First Named Inventor	Yaver et al.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	10322.200-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MORROW, Brian J. and SHAW, Karen Joy, "DNA Microarray Expression Analysis in Antibacterial Drug Discovery", Pathogen Genomics: Impact on Human Health, pp. 97-112, Humana Press Inc., Totowa, New Jersey, 2002	
		WILSON et al., "Exploring drug-induced alterations in gene expression in <i>Mycobacterium tuberculosis</i> by microarray hybridization", PNAS, October 26, 1999, Vol. 96, No. 22, p. 12833-12838	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.